Nutt takes over for Douglass as CEO of CTI Molecular Imaging
Terry D. Douglass, Ph.D., on Wednesday stepped down as president and CEO of CTI Molecular Imaging Inc.
Douglass will give the reins to fellow CTI co-founder Ronald Nutt, Ph.D. Douglass will continue as chairman of the Knoxville, Tenn. company, overseeing CTI's strategic direction.
Nutt has served as president of CPS Innovations, the CTI division that has led the company's research-and-development and manufacture of positron emission tomography (PET) technology. He has led some of PET's most significant advances, including the integration of PET and computed tomography (CT) and the commercialization of CTI's proprietary lutetium oxyorthosilicate (LSO) detector materials. In some cases, LSO technology has reduced PET whole-body scan time to less than 10 minutes.
Douglass will give the reins to fellow CTI co-founder Ronald Nutt, Ph.D. Douglass will continue as chairman of the Knoxville, Tenn. company, overseeing CTI's strategic direction.
Nutt has served as president of CPS Innovations, the CTI division that has led the company's research-and-development and manufacture of positron emission tomography (PET) technology. He has led some of PET's most significant advances, including the integration of PET and computed tomography (CT) and the commercialization of CTI's proprietary lutetium oxyorthosilicate (LSO) detector materials. In some cases, LSO technology has reduced PET whole-body scan time to less than 10 minutes.